| 1 |
urokinase-type plasminogen activator
(4092 times)
|
Neoplasms
(953 times)
|
PAI-1 (661 times)
tPA (626 times)
uPAR (508 times)
|
1983 Glucocorticoids inhibit plasminogen activator production by endothelial cells.
|
| 2 |
urokinase-type PA
(226 times)
|
Cell Biology
(34 times)
|
PA (111 times)
tPA (108 times)
PAI-1 (62 times)
|
1985 Effect of dimethyl sulfoxide on human carcinoma cells, inhibition of plasminogen activator synthesis, change in cell morphology, and alteration of response to cholera toxin.
|
| 3 |
urokinase PA
(25 times)
|
Neurology
(4 times)
|
tPA (19 times)
PA (13 times)
PAs (9 times)
|
1989 Fibrinolytic activity and localization of plasminogen activator in bovine vitreous body and aqueous humor.
|
| 4 |
urokinase-type plasminogen
(13 times)
|
Neoplasms
(5 times)
|
BD-d (2 times)
ECM (2 times)
uPAR (2 times)
|
1993 Cytokine activation of human macro- and microvessel-derived endothelial cells.
|
| 5 |
urokinase-type activator
(7 times)
|
Medicine
(2 times)
|
PLG (3 times)
tPA (3 times)
uPAR (2 times)
|
2003 Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.
|
| 6 |
unilateral PA
(4 times)
|
Endocrinology
(2 times)
|
PA (4 times)
AUC (2 times)
EH (2 times)
|
2021 The Value of Different Single or Combined Indexes of the Captopril Challenge Test in the Diagnosis of Primary Aldosteronism.
|
| 7 |
pro-urokinase
(2 times)
|
Vascular Diseases
(2 times)
|
FSAP (2 times)
FVII (2 times)
AF (1 time)
|
2008 Factor VII-activating protease (FSAP): vascular functions and role in atherosclerosis.
|
| 8 |
undifferentiated polyarthritis
(2 times)
|
Rheumatology
(2 times)
|
RA (2 times)
anti-CCP (1 time)
RF (1 time)
|
2002 One year outcome of undifferentiated polyarthritis.
|
| 9 |
urinary PA
(2 times)
|
Urology
(1 time)
|
PA (1 time)
PAI-2 (1 time)
PAI1 (1 time)
|
1995 Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
|
| 10 |
urokinase Plg activator
(2 times)
|
Biochemistry
(1 time)
|
tPA (2 times)
actMMP-9 (1 time)
Ann-II (1 time)
|
2001 Neuritogenesis and the nerve growth factor-induced differentiation of PC-12 cells requires annexin II-mediated plasmin generation.
|
| 11 |
Although plasminogen activator
(1 time)
|
Complementary Therapies
(1 time)
|
CRC (1 time)
EMT (1 time)
MMPs (1 time)
|
2019 Carnosine Suppresses Human Colorectal Cell Migration and Intravasation by Regulating EMT and MMP Expression.
|
| 12 |
anti-uPAR monoclonal antibody and proteolytically inactive urokinase
(1 time)
|
Allergy and Immunology
(1 time)
|
HUVECs (1 time)
uPAR (1 time)
|
2011 Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration.
|
| 13 |
endogenous plasminogen activator
(1 time)
|
Science
(1 time)
|
---
|
1999 Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases.
|
| 14 |
particular plasminogen activator
(1 time)
|
Neoplasms
(1 time)
|
---
|
1994 [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
|
| 15 |
ubiquitous plasminogen by cell-derived urokinase-type
(1 time)
|
Pathology
(1 time)
|
uPAR (1 time)
|
1994 Plasminogen activation in healing human wounds.
|
| 16 |
unique PA strains
(1 time)
|
Cell Biology
(1 time)
|
CF (1 time)
ePA (1 time)
|
2020 Cystic Fibrosis Patients Infected With Epidemic Pseudomonas aeruginosa Strains Have Unique Microbial Communities.
|
| 17 |
up-regulated plasminogen activator
(1 time)
|
Cell Biology
(1 time)
|
GBM (1 time)
MMPs (1 time)
|
2020 A role for caveola-forming proteins caveolin-1 and CAVIN1 in the pro-invasive response of glioblastoma to osmotic and hydrostatic pressure.
|
| 18 |
uPA on cell surface urokinase
(1 time)
|
Biochemistry
(1 time)
|
uPAR (1 time)
|
1992 Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
|
| 19 |
uPA using AssayMax human urokinase
(1 time)
|
Biochemistry
(1 time)
|
EBV-EA (1 time)
TPA (1 time)
|
2012 Synthesis and docking studies of novel antitumor benzimidazoles.
|
| 20 |
uPAR and produce urokinase
(1 time)
|
Metabolism
(1 time)
|
ALP (1 time)
AP-1 (1 time)
KO (1 time)
|
2007 Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function.
|
| 21 |
uPAR and urokinase
(1 time)
|
Biology
(1 time)
|
uPAR (1 time)
|
2020 Urokinase receptor regulates nerve regeneration through its interaction with alpha5beta1-integrin.
|
| 22 |
uPAR binding to its proteolytic ligand, urokinase
(1 time)
|
Neoplasms
(1 time)
|
rt-TA (1 time)
uPAR (1 time)
|
2007 A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines.
|
| 23 |
uPAR but undetectable levels of urokinase
(1 time)
|
Cell Biology
(1 time)
|
CK18 (1 time)
uPAR (1 time)
|
1994 Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells.
|
| 24 |
uPAR in complex with both urokinase
(1 time)
|
Molecular Biology
(1 time)
|
uPAR (1 time)
|
2008 Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.
|
| 25 |
uPAR mRNAs and a beta-globin reporter mRNA containing the ARE
(1 time)
|
Cell Biology
(1 time)
|
AREs (1 time)
MK2 (1 time)
|
2003 Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2.
|
| 26 |
uPAR primary ligand is the serine protease urokinase
(1 time)
|
|
GPI (1 time)
|
2022 Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.
|
| 27 |
uPAR purified from the ascitic fluid has no bound ligand
(1 time)
|
Medicine
(1 time)
|
---
|
1993 A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
|
| 28 |
uPAR, whether this interaction alone is critical to urokinase
(1 time)
|
Cell Biology
(1 time)
|
uPAR (1 time)
|
2008 Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.
|
| 29 |
upregulated, whereas Vimentin, N-cadherin, Plasminogen Activator, Urokinase
(1 time)
|
Biotechnology
(1 time)
|
AQP5 (1 time)
EMT (1 time)
MMP (1 time)
|
2018 Anti-cancer effect of Aquaporin 5 silencing in colorectal cancer cells in association with inhibition of Wnt/beta-catenin pathway.
|
| 30 |
upstream regions of the human urokinase
(1 time)
|
Hematology
(1 time)
|
JNK (1 time)
MAPK (1 time)
MP (1 time)
|
2004 MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription.
|
| 31 |
uridylyl phosphate adenosine
(1 time)
|
Bioengineering
(1 time)
|
ATF7 (1 time)
lncRNA (1 time)
PCAT18 (1 time)
|
2021 lncRNA prostate cancer-associated transcript 18 upregulates activating transcription factor 7 to prevent metastasis of triple-negative breast cancer via sponging miR-103a-3p.
|
| 32 |
urinary plasminogen activator or urokinase
(1 time)
|
Neoplasms
(1 time)
|
ruPAR (1 time)
uPAR (1 time)
|
2002 Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
|
| 33 |
urinary-type
(1 time)
|
Dentistry
(1 time)
|
---
|
2010 Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
|
| 34 |
Urokinase Activation Plasminogen
(1 time)
|
Medicine
(1 time)
|
ER (1 time)
PgR (1 time)
|
2018 Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
|
| 35 |
urokinase protein
(1 time)
|
Neoplasms
(1 time)
|
aFGF (1 time)
bFGF (1 time)
ELISA (1 time)
|
1998 Autocrine self-elimination of cultured ovarian cancer cells by tumour necrosis factor alpha (TNF-alpha).
|
| 36 |
urokinase-type plasminogen activation system including urokinase
(1 time)
|
Pharmacy
(1 time)
|
GFD (1 time)
|
2019 Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations.
|
| 37 |
urotype PA
(1 time)
|
Dentistry
(1 time)
|
HGF (1 time)
PA (1 time)
PAI-1 (1 time)
|
1999 Enhancement of LPS-stimulated plasminogen activator production in aged gingival fibroblasts.
|
| 38 |
used as a therapeutic inhibitor of urokinase
(1 time)
|
Biochemistry
(1 time)
|
alpha 1-PI (1 time)
CT (1 time)
PAI-1 (1 time)
|
1990 Plasminogen activator inhibitor 2 (PAI-2) is not inactivated by exposure to oxidants which can be released from activated neutrophils.
|
| 39 |
Using a CDCP1-biased probe, we identify urokinase
(1 time)
|
Biology
(1 time)
|
CDCP1 (1 time)
sbABP (1 time)
|
2021 Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1.
|
A Search Service for Abbreviation / Long Form